Quantum X Labs Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 18, 2026, reporting financial results and balance sheet changes for the nine and three months ended on that date.

Key Highlights

  • Quarterly net loss: Net loss attributable to shareholders of Quantum X Labs Inc. for the three months ended September 30, 2026 was $5,879 thousand, compared with $3,393 thousand in the same period of 2025, according to the filing.
  • Nine-month revenue decline: Revenues for the nine months ended September 30, 2026 were $900 thousand, down from $1,300 thousand in the comparable prior-year period, the filing disclosed.
  • Share count increase: Common shares issued and outstanding rose to 21,867,826 as of September 30, 2026 from 10,670,392 as of December 31, 2025, the filing stated.
  • Total assets growth: Total assets were reported at $28,867 thousand as of September 30, 2026, compared with $10,757 thousand as of December 31, 2025.
  • Accumulated deficit: The accumulated deficit stood at $50,046 thousand as of September 30, 2026, up from $46,047 thousand at December 31, 2025, per the filing.
  • Loss from deconsolidation: The filing reported a loss from deconsolidation of CliniQuantum of $3,840 thousand in the three months ended September 30, 2026.
  • Warrant exercises: During the nine-month period, 7,887,987 warrants were exercised, adding $4,036 thousand to equity, the filing disclosed.

Quantum X Labs Q3 2026 Financial Results and Balance Sheet Changes

Quantum X Labs Inc. (NASDAQ:QXL), formerly known as Viewbix Inc., reported an operating loss of $2,048 thousand for the three months ended September 30, 2026, compared with an operating loss of $525 thousand for the same period in 2025, according to the filing. For the nine months ended September 30, 2026, the operating loss was $3,993 thousand versus $1,603 thousand in the prior-year period. The company reported revenues of $254 thousand for the third quarter of 2026 and $900 thousand for the nine-month period ended September 30, 2026.

The filing disclosed a loss from deconsolidation of CliniQuantum of $3,840 thousand in the three-month period ended September 30, 2026, which was a significant contributor to the total loss from continuing operations before taxes of $6,001 thousand for that quarter. For the nine months ended September 30, 2026, financial expenses, net were $224 thousand, a substantial reduction from $11,173 thousand in the same period of 2025. The basic and diluted net loss per share attributable to shareholders from continuing operations was $(0.28) for the three months and $(0.25) for the nine months ended September 30, 2026, based on weighted average shares of 21,326,252 and 15,742,044, respectively.

On the balance sheet, total equity attributable to shareholders of Quantum X Labs Inc. increased to $22,391 thousand as of September 30, 2026 from $4,989 thousand at December 31, 2025, primarily reflecting the issuance of shares in connection with the acquisition of a subsidiary (adding $15,171 thousand to additional paid-in capital), warrant exercises, and a private placement. Intangible assets, net rose to $10,352 thousand from $2,045 thousand, and goodwill increased to $10,229 thousand from $6,392 thousand over the same period. The filing noted that the registrant had 22,125,921 shares of common stock issued and outstanding as of November 18, 2026.

What Was Disclosed

Quantum X Labs Inc. filed its unaudited interim condensed consolidated financial statements for the quarterly period ended September 30, 2026, disclosing revenue, operating losses, balance sheet changes, share issuances, warrant exercises, and the deconsolidation of subsidiary CliniQuantum during the period.